产品中心 抗体 其他一抗

所有图片(1/2)

KCNQ2 Recombinant Rabbit mAb (S-3465-49)

Potassium voltage-gated channel subfamily KQT member 2,KQT-like 2,Neuroblastoma-specific potassium channel subunit alpha KvLQT2,Voltage-gated potassium channel subunit Kv7.2

价格 600.00 供应商现货 : 3-5个工作日
货号 S0B6721
规格
数量
收藏 分享

产品介绍 评论(0)

产品规格
  • 宿主来源

    Rabbit
  • 抗原名称

    KCNQ2
  • 分子别名

    Potassium voltage-gated channel subfamily KQT member 2; KQT-like 2; Neuroblastoma-specific potassium channel subunit alpha KvLQT2; Voltage-gated potassium channel subunit Kv7.2
  • 免疫原

    Synthetic Peptide
  • 细胞定位

    Cell membrane
  • Accession

    O43526
  • 克隆号

    S-3465-49
  • 抗体类型

    Recombinant mAb
  • 抗体同种型

    IgG
  • 反应种属 ?

    Hu, Ms, Rt
  • 阳性样本

    mouse brain, rat brain
  • 纯化方式

    Protein A
  • 浓度

    2 mg/ml
  • 标记

    Unconjugated
  • 性状

    Liquid
  • 缓冲体系

    PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300

  • 储存条件

    12 months from date of receipt / reconstitution, -20 °C as supplied

  • 应用

    WB

  • 稀释度

    应用 稀释度 推荐种属
    WB 1:1000 Hu, Ms, Rt
背景介绍
  • The KCNQ2 protein is a voltage-gated potassium channel α-subunit, encoded by the KCNQ2 gene, that plays a critical role in regulating neuronal excitability throughout the central nervous system. Predominantly expressed in the brain, KCNQ2 primarily forms heterotetrameric complexes with KCNQ3 subunits to constitute the M-current (IKM), a slowly activating, non-inactivating potassium current that acts as a crucial brake on repetitive neuronal firing by stabilizing the resting membrane potential and preventing excessive depolarization. Functionally, this current is activated at subthreshold membrane potentials and is essential for controlling action potential threshold, firing frequency, and burst accommodation in neurons. Clinically, mutations in KCNQ2 are associated with a spectrum of epileptic disorders, ranging from benign familial neonatal epilepsy (BFNE) to severe developmental and epileptic encephalopathies (DEE) characterized by refractory seizures, intellectual disability, and neurodevelopmental impairment. The KCNQ2 channel serves as the primary pharmacological target for retigabine (ezogabine), an antiepileptic drug that activates the channel by inducing a conformational shift favoring the open state, thereby enhancing the M-current and reducing neuronal hyperexcitability. Structurally, KCNQ2 contains six transmembrane domains (S1-S6), with the S4 segment functioning as the voltage sensor and the S5-S6 loop forming the channel pore, while intracellular domains mediate subunit assembly, trafficking, and calmodulin-dependent regulation of channel gating kinetics.

  • 免疫印迹

    • WB result of KCNQ2 Recombinant Rabbit mAb
      Primary antibody: KCNQ2 Recombinant Rabbit mAb at 1/1000 dilution
      Lane 1: mouse brain lysate 20 µg
      Secondary antibody: Goat Anti- rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
      Predicted MW: 96 kDa
      Observed MW: 14, 105 kDa

    • WB result of KCNQ2 Recombinant Rabbit mAb
      Primary antibody: KCNQ2 Recombinant Rabbit mAb at 1/1000 dilution
      Lane 1: rat brain lysate 20 µg
      Secondary antibody: Goat Anti- rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
      Predicted MW: 96 kDa
      Observed MW: 14, 105 kDa

评论(0)